Sophisticated new prostate cancer tests are coming to market that might supplement the unreliable P.S.A. test, potentially saving tens of thousands of men each year from unnecessary biopsies, operations and radiation treatments.
Read the full article on the New York Times.
In the world of early disease detection, Mitomics Inc. is pioneering the next generation of molecular testing. The Thunder Bay-based company is charting new territory with an innovative approach to the screening and diagnosis of cancer by using mitochondrial DNA (mtDNA) based biomarkers instead of traditional nuclear DNA-based biomarkers.
Read the full article on the Biotechnolgy Focus website.
Titanic’s unknown child: The critical role of the mitochondrial DNA coding region in a re-identification effort.
Read the full report on the ScienceDirect website.
ARUP Labs plans to begin offering Decode’s prostate cancer-risk test to clients nationwide in the fall, the companies said.
Continue reading “ARUP to offer Decode’s prostate cancer risk test, but Mitomics catching up”
Over the last 20 years, the world has poured billions of dollars and hours into cancer research, plumbing the depths of our DNA in search of a cure. We’ve discovered causes, treatments and ways to diagnose and detect the disease, yet as of right now, the cure remains a mystery, hidden somewhere, many scientists say, in the complex workings of our nuclear DNA. Some experts, however, disagree. Some believe that the key to abolishing cancer lies in the much less studied mitochondrial DNA (mtDNA). Some believe so wholeheartedly that it lies in the mtDNA, they are willing to stake their reputations and livelihood on it. The founders of Thunder Bay’s Genesis Genomics Inc. did just that, and are producing some staggering results. This begs the question: have we been looking in the wrong place?
Continue reading “A New Perspective – Genesis Genomics turns cancer research on its head with research showing the keys to cancer lie in mitochondrial DNA, not nuclear DNA”